The Cervical Cancer (CC) Epidemiology and Human Papillomavirus (HPV) in the Middle East
Viral infections contribute 15–20 percent of all human cancers as a cause. Oncogenic virus infection may spur various stages of carcinogenesis. For several forms for HPV, about 15 associated with cancer. Following successful test techniques, cervical cancer remains a significant public health issue. Prevalence and mortality of per geographic area of cervical cancer were vastly different. The fourth most common cause of death from cancer among women is cervical cancer (CC). Human papillomavirus (HPV) infection in the cervix is the most significant risk factor for forming cervical cancer. Inflammation is a host-driven defensive technique that works rapidly to stimulate the innate immune response against pathogens such as viral infections. Inflammation is advantageous if it is brief and well-controlled; however, it can cause adverse effects if the inflammation is prolonged or is chronic in duration. HPV proteins are involved in the production of chronic inflammation, both directly and indirectly. Also, the age-specific prevalence of HPV differs significantly. Two peaks of HPV positive in younger and older people have seen in various populations. A variety of research has performed worldwide on the epidemiology of HPV infection and oncogenic properties due to specific HPV genotypes. Nevertheless, there are still several countries where population-dependent incidences have not yet identified. Additionally, the methods of screening for cervical cancer differ among countries.
J. M. M. Walboomers et al., “Human papillomavirus is a necessary cause of invasive cervical cancer worldwide,” J. Pathol., vol. 189, no. 1, pp. 12–19, 1999.
C. L. Satterwhite et al., “Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008,” Sex. Transm. Dis., vol. 40, no. 3, pp. 187–193, 2013.
J. A. Tiro, H. I. Meissner, S. Kobrin, and V. Chollette, “What do women in the US know about human papillomavirus and cervical cancer?,” Cancer Epidemiol. Prev. Biomarkers, vol. 16, no. 2, pp. 288–294, 2007.
E. WHO, “Preventing chronic diseases: a vital investment,” World Health, vol. 202, 2005.
I. Zündorf, “Infections Causing Human Cancer. Von H. zur Hausen,” Pharm. Unserer Zeit, vol. 36, no. 1, pp. 70–71, 2007.
P. K. S. Chan, M. A. Picconi, T. H. Cheung, L. Giovannelli, and J. S. Park, “Laboratory and clinical aspects of human papillomavirus testing,” Crit. Rev. Clin. Lab. Sci., vol. 49, no. 4, pp. 117–136, 2012.
D. Saslow et al., “American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer,” CA. Cancer J. Clin., vol. 62, no. 3, pp. 147–172, 2012.
S. Alder, Prevention of cervical cancer in countries with a high and low incidence of the disease. Inst för kvinnors och barns hälsa/Dept of Women’s and Children’s Health, 2018.
L. Sichero, M. A. Picconi, and L. L. Villa, “The contribution of Latin American research to HPV epidemiology and natural history knowledge,” Brazilian J. Med. Biol. Res., vol. 53, no. 2, 2020.
M. Burley, S. Roberts, and J. L. Parish, “Epigenetic regulation of human papillomavirus transcription in the productive virus life cycle,” in Seminars in Immunopathology, 2020, pp. 1–13.
H. Trottier and E. L. Franco, “The epidemiology of genital human papillomavirus infection,” Vaccine, vol. 24, pp. S4–S15, 2006.
L. Alemany et al., “Role of human papillomavirus in penile carcinomas worldwide,” Eur. Urol., vol. 69, no. 5, pp. 953–961, 2016.
R. Wang et al., “Human papillomavirus vaccine against cervical cancer: Opportunity and challenge,” Cancer Lett., vol. 471, pp. 88–102, 2020.
N. Guimera, L. Alemany, L. Bruni, and N. Muñoz, “Demonstrating the Importance of Different HPVs in Cervical Cancer and Other HPV-Related Cancers,” in Human Papillomavirus, Elsevier, 2020, pp. 41–51.
A. T. Jalil, S. H. Dilfi, and A. Karevskiy, “Survey of Breast Cancer in Wasit Province, Iraq,” Glob. J. Public Heal. Med., vol. 1, no. 2, pp. 33–38, 2019.
S. Vaccarella, M. Laversanne, J. Ferlay, and F. Bray, “Cervical cancer in A frica, L atin A merica and the C aribbean and A sia: Regional inequalities and changing trends,” Int. J. cancer, vol. 141, no. 10, pp. 1997–2001, 2017.
R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2019,” CA. Cancer J. Clin., vol. 69, no. 1, pp. 7–34, 2019.
O. Ginsburg et al., “The global burden of women’s cancers: a grand challenge in global health,” Lancet, vol. 389, no. 10071, pp. 847–860, 2017.
R. Busuttil, C. Galdies, J. Cacciottolo, and C. Yousif, “Climatological Global Solar UV Index: Measurement and Health Issues in Malta,” in Handbook of Climate Services, Springer, 2020, pp. 253–277.
Y. B. Mlombe et al., “Environmental risk factors for oesophageal cancer in Malawi: A case-control study,” Malawi Med. J., vol. 27, no. 3, pp. 88–92, 2015.
L. Denny et al., “Interventions to close the divide for women with breast and cervical cancer between low-income and middle-income countries and high-income countries,” Lancet, vol. 389, no. 10071, pp. 861–870, 2017.
D. Osok, S. Karanja, Y. Kombe, E. Njuguna, and J. Todd, “Assessing Factors Associated With Survival Among Cervical Cancer Patients in Kenya: A Retrospective Follow-up Study,” EA Heal. Res. J., vol. 2, no. 2, pp. 118–127, 2018.
S. Finocchario-Kessler, C. Wexler, M. Maloba, N. Mabachi, F. Ndikum-Moffor, and E. Bukusi, “Cervical cancer prevention and treatment research in Africa: a systematic review from a public health perspective,” BMC Womens. Health, vol. 16, no. 1, p. 29, 2016.
L. Denny and R. Anorlu, “Cervical cancer in Africa,” Cancer Epidemiol. Prev. Biomarkers, vol. 21, no. 9, pp. 1434–1438, 2012.
D. S. Alberts and L. M. Hess, “Introduction to cancer prevention,” in Fundamentals of Cancer Prevention, Springer, 2019, pp. 1–16.
E. Wiebe, L. Denny, and G. Thomas, “Cancer of the cervix uteri,” Int. J. Gynecol. Obstet., vol. 119, pp. S100–S109, 2012.
J. H. Shepherd, “Cervical cancer,” Best Pract. Res. Clin. Obstet. Gynaecol., vol. 26, no. 3, pp. 293–309, 2012.
T. Zigras, G. Lennox, K. Willows, and A. Covens, “Early cervical cancer: current dilemmas of staging and surgery,” Curr. Oncol. Rep., vol. 19, no. 8, p. 51, 2017.
M. Mistrangelo et al., “Role of positron emission tomography-computed tomography in the management of anal cancer,” Int. J. Radiat. Oncol. Biol. Phys., vol. 84, no. 1, pp. 66–72, 2012.
G. İ. İmamoğlu et al., “The impact of lymph node ratio on overall survival in patients with colorectal cancer,” 2020.
J. Evans, U. Patel, and G. Brown, “Rectal cancer: primary staging and assessment after chemoradiotherapy,” in Seminars in radiation oncology, 2011, vol. 21, no. 3, pp. 169–177.
E. A. White, “Manipulation of Epithelial Differentiation by HPV Oncoproteins,” Viruses, vol. 11, no. 4, p. 369, 2019.
T. Khan, C. L. Heffron, K. P. High, and P. C. Roberts, “Tailored vaccines targeting the elderly using whole inactivated influenza vaccines bearing cytokine immunomodulators,” J. Interf. Cytokine Res., vol. 34, no. 2, pp. 129–139, 2014.
A. Kabir, M. Bukar, H. A. Nggada, H. B. Rann, A. Gidado, and A. B. Musa, “Prevalence of human papillomavirus genotypes in cervical cancer in Maiduguri, Nigeria,” Pan Afr. Med. J., vol. 33, 2019.
R. A. Anderson, R. T. Mitchell, T. W. Kelsey, N. Spears, E. E. Telfer, and W. H. B. Wallace, “Cancer treatment and gonadal function: experimental and established strategies for fertility preservation in children and young adults,” lancet Diabetes Endocrinol., vol. 3, no. 7, pp. 556–567, 2015.
W.-J. Koh et al., “Cervical Cancer,” J. Natl. Compr. Cancer Netw., vol. 13, no. 4, pp. 395–404, 2015.
C.-F. Hung, B. Ma, A. Monie, S.-W. Tsen, and T. C. Wu, “Therapeutic human papillomavirus vaccines: current clinical trials and future directions,” Expert Opin. Biol. Ther., vol. 8, no. 4, pp. 421–439, 2008.
A. K. Chaudhary, S. Pandya, R. Mehrotra, A. C. Bharti, M. Singh, and M. Singh, “Comparative study between the Hybrid Capture II test and PCR based assay for the detection of human papillomavirus DNA in oral submucous fibrosis and oral squamous cell carcinoma,” Virol. J., vol. 7, no. 1, p. 253, 2010.
M. A. Stanley, “Genital human papillomavirus infections: current and prospective therapies,” J. Gen. Virol., vol. 93, no. 4, pp. 681–691, 2012.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-ShareAlike 4.0 (CC BY SA) International License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See the Effect of Open Access).